The store will not work correctly when cookies are disabled.
Platinum complex
ID: ALA262033
Max Phase: Preclinical
Molecular Formula: C44H30N12O12Pt2+8
Molecular Weight: 1308.95
Molecule Type: Small molecule
Associated Items:
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Properties
Molecular Weight: 1308.95 | Molecular Weight (Monoisotopic): 1308.1358 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
References
1. Lowe G, Droz AS, Vilaivan T, Weaver GW, Park JJ, Pratt JM, Tweedale L, Kelland LR.. (1999) Cytotoxicity of 2,2':6',2' '-terpyridineplatinum(II) complexes against human ovarian carcinoma., 42 (16): [PMID:10447962] [10.1021/jm991053y] |